PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1620439
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1620439
Point of Care Infectious Disease Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
The Global Point Of Care Infectious Disease Testing Market was valued at USD 3.2 billion in 2023 and is anticipated to grow at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2032. Point-of-care infectious disease testing refers to diagnostic tests performed near or at the site of patient care, providing rapid results that facilitate immediate clinical decision-making, without the need for centralized laboratories. One of the main factors driving the expansion of the POC infectious disease testing market is the rising global burden of infectious diseases. The emergence of new pathogens, the resurgence of diseases that were previously under control, and the increasing threat of antimicrobial resistance underscore the critical need for rapid and accurate diagnostic solutions. Diseases such as influenza, HIV, hepatitis, and tuberculosis continue to pose significant health challenges worldwide, further boosting the demand for POC testing.
Technological advancements are playing a crucial role in accelerating the adoption of POC infectious disease testing. Innovations in device miniaturization, the integration of digital platforms, and the development of rapid molecular testing have significantly improved the portability, accuracy, and speed of these diagnostics. Automated devices with real-time data-sharing capabilities are transforming the efficiency of point-of-care testing, making them highly valuable in remote or resource-constrained settings where access to traditional laboratories may be limited. Furthermore, the convenience of on-the-spot results provided by POC tests is increasingly favored by healthcare providers and patients alike, as it leads to more efficient patient management and better health outcomes.
This is particularly important in managing infectious diseases where timely diagnosis can significantly impact treatment decisions and help control the spread of infections. With the global healthcare industry placing a stronger emphasis on early detection and rapid treatment, the POC infectious disease testing market is set to experience sustained growth. This growth is further supported by an increasing focus on improving healthcare access in underserved regions, as well as ongoing investments in research and development aimed at enhancing test accuracy and reducing costs. Overall, the combination of rising healthcare needs, technological innovation, and demand for quick, actionable diagnostic information positions the point-of-care infectious disease testing market for continued expansion in the coming years.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $3.2 Billion |
| Forecast Value | $5.9 Billion |
| CAGR | 6.9% |
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of infectious diseases
- 3.2.1.2 Technological advancements in point of care testing devices
- 3.2.1.3 Growing awareness among people for point of care testing
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High development cost of POC tests
- 3.2.2.2 Concerns about accuracy and reliability
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Future market trends
- 3.7 Gap analysis
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Kits and reagents
- 5.3 Instruments
Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Molecular diagnostics
- 6.3 Lateral flow immunoassay
- 6.4 Agglutination test
- 6.5 Flow-through Test/Immunoconcentration assay
- 6.6 Other technologies
Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Tropical diseases
- 7.3 Liver diseases
- 7.4 Respiratory diseases
- 7.5 Hospital associated infections
- 7.6 Sexual health disorders
- 7.7 Other applications
Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Diagnostic centers
- 8.4 Research and academic institutes
- 8.5 Homecare settings
- 8.6 Others end users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Becton, Dickinson and Company
- 10.3 Biomerieux
- 10.4 Bio-Rad Laboratories
- 10.5 Cardinal Health
- 10.6 Chembio Diagnostics
- 10.7 Danaher Corporation
- 10.8 F. Hoffmann-La Roche
- 10.9 OJ-Bio
- 10.10 QuidelOrtho Corporation
- 10.11 Siemens Healthineers
- 10.12 Trinity Biotech
- 10.13 Trivitron Healthcare
